Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
The Scottish National Party has put the NHS, EU membership and Scottish independence at the heart of its campaign as the UK prepares to vote in the 12 December general election.
Latest From Brexit
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.
UK health minister Baroness Blackwood will introduce the new UK Medicines and Medical Devices Bill before Parliament today, just before the House of Commons goes into recess. The government wants new legislation for devices and medicines in place before the end of the Brexit transition period.
EU medical device consultant Trevor Lewis takes note of the recent, if belated, progress towards the building of the post-MDR playing field for medical device companies in Europe, but calls political decision-makers and economic operators to account: getting it right is nothing short of a matter of life and death, he tells In Vivo.
Partnership includes provision for fast-tracked uptake of inclisiran in England, if NICE finds it cost effective.
As the EMA settles into its permanent headquarters in Amsterdam, it hopes that new recruits will swell its depleted staff numbers. But much will depend on the necessary expertise being available, particularly following the loss of access to experts working at the UK regulator, the MHRA.
In this week's podcast, Medtech Insight executive editor Ashley Yeo chats with deputy editor Reed Miller about the UK's departure from the EU on 31 January, and what that means for the region's medtech industry.
As the UK prepares for talks on post-Brexit free trade agreements with the EU and other countries around the world, the life science industry has called for a specific pharmaceutical annex in any FTAs.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.